Agenus (AGEN) Expected to Announce Earnings on Monday

Agenus (NASDAQ:AGEN) is expected to release its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect Agenus to post earnings of $1.95 per share and revenue of $129.50 million for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:00 PM ET.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Monday, March 16th. The biotechnology company reported $0.56 EPS for the quarter, topping the consensus estimate of ($1.27) by $1.83. Agenus had a negative net margin of 2.67% and a negative return on equity of 7.65%. The business had revenue of $34.20 million for the quarter, compared to analyst estimates of $28.10 million. On average, analysts expect Agenus to post $1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Agenus Stock Up 0.6%

Shares of NASDAQ AGEN traded up $0.02 on Monday, reaching $3.86. 181,178 shares of the company’s stock traded hands, compared to its average volume of 749,271. Agenus has a 12 month low of $2.71 and a 12 month high of $7.34. The business’s 50 day simple moving average is $3.66 and its two-hundred day simple moving average is $3.68. The company has a market cap of $148.37 million, a price-to-earnings ratio of -8.38 and a beta of 1.60.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Zacks Research raised Agenus from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 2nd. Wall Street Zen raised Agenus from a “hold” rating to a “buy” rating in a research report on Monday, April 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $14.50.

Institutional Trading of Agenus

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in shares of Agenus by 1.5% in the third quarter. Vanguard Group Inc. now owns 2,569,533 shares of the biotechnology company’s stock worth $9,893,000 after purchasing an additional 36,983 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Agenus by 721.1% in the 4th quarter. Renaissance Technologies LLC now owns 543,546 shares of the biotechnology company’s stock worth $1,707,000 after buying an additional 477,346 shares in the last quarter. AQR Capital Management LLC increased its holdings in Agenus by 3,080.3% in the 1st quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock worth $664,000 after buying an additional 427,604 shares in the last quarter. Marshall Wace LLP purchased a new position in Agenus in the 2nd quarter worth about $1,976,000. Finally, Bank of America Corp DE lifted its stake in Agenus by 110.0% during the 2nd quarter. Bank of America Corp DE now owns 420,678 shares of the biotechnology company’s stock valued at $1,922,000 after acquiring an additional 220,327 shares during the period. Institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.